Roche’s Avastin Fails to Help Early-Stage Colon Cancer Patients in Study

Bloomberg -- Roche Holding AG’s Avastin tumor medicine failed to meet the main goal of a late-stage study in early colon cancer.

MORE ON THIS TOPIC